---
title: "Pharvaris N.V. Stock 12‑Month Price Target Cut to $46.6, Implies 49% Upside"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286240488.md"
description: "Pharvaris N.V.'s 12-month stock price target has been reduced from $46.85 to $46.6, suggesting a potential upside of 49% based on the May 12 closing price. The consensus rating remains a \"Buy\" from 14 analysts, with 13 recommending buys and 1 hold. Price forecasts range from $30.9 to $74.02 per share."
datetime: "2026-05-13T10:20:06.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286240488.md)
  - [en](https://longbridge.com/en/news/286240488.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286240488.md)
---

# Pharvaris N.V. Stock 12‑Month Price Target Cut to $46.6, Implies 49% Upside

-   According to estimates from 14 analysts, Pharvaris N.V. stock's average price target has fallen from $46.85 to $46.6, with forecasts ranging from $30.9 to $74.02 per share
-   Based on the May 12 closing price, the updated target implies approximately 49% potential upside
-   Consensus rating remains at “Buy” across 14 covering analysts, with 13 Buys, 1 Holds and 0 Sells

Explore more price target data and ratings for Pharvaris N.V. on the , and track all previous and future analyst recommendations for Pharvaris N.V. in the dedicated News Flow.

**Disclaimer**

Select reference data provided by FactSet. Copyright © 2026 FactSet Research Systems Inc. This information is not a recommendation for what you should do personally and does not constitute investment advice.

### Related Stocks

- [PHVS.US](https://longbridge.com/en/quote/PHVS.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [VHT.US](https://longbridge.com/en/quote/VHT.US.md)
- [XLV.US](https://longbridge.com/en/quote/XLV.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [IXJ.US](https://longbridge.com/en/quote/IXJ.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [IHE.US](https://longbridge.com/en/quote/IHE.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)

## Related News & Research

- [NeOnc Advances Glioma Programs and Strengthens Financial Position](https://longbridge.com/en/news/286826865.md)
- [LifeSci Capital Sticks to Their Buy Rating for Tenax Therapeutics (TENX)](https://longbridge.com/en/news/286648286.md)
- [Acrivon Therapeutics, Inc. (ACRV) Receives a Buy from Oppenheimer](https://longbridge.com/en/news/286428001.md)
- [14:05 ETLupin Receives Tentative Approval from U.S. FDA for Revefenacin Inhalation Solution](https://longbridge.com/en/news/286805922.md)
- [Roth MKM Sticks to Their Buy Rating for Capricor Therapeutics (CAPR)](https://longbridge.com/en/news/286497683.md)